Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Morgane Mailhe, Barbara Doudier, Johan Courjon, Valérie Giordanengo, Vera Esteves Vieira, Hervé Tissot Dupont, Stéphane Honoré, Philippe Colson, Eric Chabrière, Bernard La Scola, Jean-Marc Rolain, Philippe Brouqui, Didier Raoult
International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.105949
Background: Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the effect of hydroxychloroquine on respiratory viral loads. Patients and methods: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16 th , to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point. Results: Six patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported in the litterature for untreated patients. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination. Conclusion: Despite its small sample size, our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
Declarations
Supplementary material Supplementary material associated with this article can be found, in the online version, at doi: 10.1016/j.ijantimicag.2020. 105949 .
References
Amrane, Tissot-Dupont, Doudier, Eldin, Hocquart et al., Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, -January 31st to March 1st, 2020: A respiratory virus snapshot, Travel Med Infect Dis
Armstrong, Richez, Raoult, Chabriere, Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple's disease, B Analyt. Technol. Biomed. Life Sci
Bacharier, Guilbert, Mauger, Boehmer, Beigelman et al., Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: A randomized clinical trial, JAMA,
doi:10.1001/jama.2015.13896Biot, Daher, Chavain, Fandeur, Khalife et al., Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities, J Med Chem
Bosseboeuf, Aubry, Nhan, De Pina, Rolain et al., Azithromycin inhibits the replication of Zika virus, J Antivirals Antiretrovirals,
doi:10.4172/1948-5964.1000173Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends,
doi:10.5582/bst.2020.01047Lagier, Raoult, Whipple's disease and Tropheryma whipplei infections: when to suspect them and how to diagnose and treat them, Zhonghua Jie He He Hu Xi Za Zhi,
doi:10.1097/QCO.0000000000000489Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105924Madrid, Panchal, Warren, Shurtleff, Endsley et al., Evaluation of Ebola Virus Inhibitors for Drug Repurposing, ACS Infect Dis,
doi:10.1021/acsinfecdis.5b00030Marmor, Kellner, Lai, Melles, Mieler et al., Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision), Ophthalmology Jun,
doi:10.1016/j.ophtha.2016.01.058Raoult, Houpikian, Dupont, Riss, Arditi-Djiane et al., Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine, Arch Intern Med
Retallack, Lullo, Arias, Knopp, Laurie et al., Zika virus cell tropism in the developing human brain and inhibition by azithromycin, Proc Natl Acad Sci U S A
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Wang, Ye, Liu, A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence, Int J Antimicrob Agents
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA,
doi:10.1001/jama.2020.2648Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3DOI record:
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"ISSN": [
"0924-8579"
],
"URL": "http://dx.doi.org/10.1016/j.ijantimicag.2020.105949",
"alternative-id": [
"S0924857920300996"
],
"article-number": "105949",
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "International Journal of Antimicrobial Agents"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.ijantimicag.2020.105949"
},
{
"label": "Content Type",
"name": "content_type",
"value": "article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2020 Published by Elsevier B.V."
}
],
"author": [
{
"affiliation": [],
"family": "Gautret",
"given": "Philippe",
"sequence": "first"
},
{
"affiliation": [],
"family": "Lagier",
"given": "Jean-Christophe",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Parola",
"given": "Philippe",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Hoang",
"given": "Van Thuan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Meddeb",
"given": "Line",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Mailhe",
"given": "Morgane",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Doudier",
"given": "Barbara",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Courjon",
"given": "Johan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Giordanengo",
"given": "Valérie",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Vieira",
"given": "Vera Esteves",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Tissot Dupont",
"given": "Hervé",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Honoré",
"given": "Stéphane",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Colson",
"given": "Philippe",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Chabrière",
"given": "Eric",
"sequence": "additional"
},
{
"affiliation": [],
"family": "La Scola",
"given": "Bernard",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Rolain",
"given": "Jean-Marc",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Brouqui",
"given": "Philippe",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Raoult",
"given": "Didier",
"sequence": "additional"
}
],
"container-title": "International Journal of Antimicrobial Agents",
"container-title-short": "International Journal of Antimicrobial Agents",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"clinicalkey.fr",
"clinicalkey.jp",
"clinicalkey.es",
"clinicalkey.com.au",
"clinicalkey.com",
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2020,
3,
20
]
],
"date-time": "2020-03-20T16:28:15Z",
"timestamp": 1584721695000
},
"deposited": {
"date-parts": [
[
2022,
7,
3
]
],
"date-time": "2022-07-03T15:56:06Z",
"timestamp": 1656863766000
},
"indexed": {
"date-parts": [
[
2024,
4,
8
]
],
"date-time": "2024-04-08T08:29:42Z",
"timestamp": 1712564982928
},
"is-referenced-by-count": 3245,
"issue": "1",
"issued": {
"date-parts": [
[
2020,
7
]
]
},
"journal-issue": {
"issue": "1",
"published-print": {
"date-parts": [
[
2020,
7
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
7,
1
]
],
"date-time": "2020-07-01T00:00:00Z",
"timestamp": 1593561600000
}
},
{
"URL": "http://www.elsevier.com/open-access/userlicense/1.0/",
"content-version": "am",
"delay-in-days": 388,
"start": {
"date-parts": [
[
2021,
7,
24
]
],
"date-time": "2021-07-24T00:00:00Z",
"timestamp": 1627084800000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0924857920300996?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0924857920300996?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "105949",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2020,
7
]
]
},
"published-print": {
"date-parts": [
[
2020,
7
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.1016/j.ijantimicag.2020.105924",
"article-title": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges",
"author": "Lai",
"doi-asserted-by": "crossref",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.ijantimicag.2020.105949_bib0001",
"year": "2020"
},
{
"article-title": "A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence”",
"author": "Wang",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.ijantimicag.2020.105949_bib0002",
"year": "2020"
},
{
"key": "10.1016/j.ijantimicag.2020.105949_bib0003",
"unstructured": "WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020]"
},
{
"DOI": "10.1001/jama.2020.2648",
"article-title": "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention",
"author": "Wu",
"doi-asserted-by": "crossref",
"journal-title": "JAMA",
"key": "10.1016/j.ijantimicag.2020.105949_bib0004",
"year": "2020"
},
{
"key": "10.1016/j.ijantimicag.2020.105949_bib0005",
"unstructured": "Santé Publique France. Infection au nouveau Coronavirus (SARS-CoV-2), COVID-19, France et Monde [https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/articles/infection-au-nouveau-coronavirus-sars-cov-2-covid-19-france-et-monde]"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105923",
"article-title": "Chloroquine for the 2019 novel coronavirus SARS-CoV-2",
"author": "Colson",
"doi-asserted-by": "crossref",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.ijantimicag.2020.105949_bib0006",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105932",
"article-title": "Chloroquine and hydroxychloroquine as available weapons to fight COVID-19",
"author": "Colson",
"doi-asserted-by": "crossref",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.ijantimicag.2020.105949_bib0007",
"year": "2020"
},
{
"article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
"author": "Wang",
"first-page": "10",
"journal-title": "Cell Res",
"key": "10.1016/j.ijantimicag.2020.105949_bib0008",
"year": "2020"
},
{
"DOI": "10.5582/bst.2020.01047",
"article-title": "Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies",
"author": "Gao",
"doi-asserted-by": "crossref",
"journal-title": "Biosci Trends",
"key": "10.1016/j.ijantimicag.2020.105949_bib0009",
"year": "2020"
},
{
"key": "10.1016/j.ijantimicag.2020.105949_bib0010",
"unstructured": "Chinese Clinical Trial Registry. http://www.chictr.org.cn/searchproj.aspx?title=%E6%B0%AF%E5%96%B9&officialname=&subjectid=&secondaryid=&applier=&studyleader=ðicalcommitteesanction=&sponsor=&studyailment=&studyailmentcode=&studytype=0&studystage=0&studydesign=0&minstudyexecutetime=&maxstudyexecutetime=&recruitmentstatus=0&gender=0&agreetosign=&secsponsor=®no=®status=0&country=&province=&city=&institution=&institutionlevel=&measure=&intercode=&sourceofspends=&createyear=0&isuploadrf=&whetherpublic=&btngo=btn&verifycode=&page=1."
},
{
"article-title": "Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]",
"first-page": "185",
"issue": "3",
"journal-title": "Zhonghua Jie He He Hu Xi Za Zhi",
"key": "10.1016/j.ijantimicag.2020.105949_bib0011",
"volume": "43",
"year": "2020"
},
{
"DOI": "10.1021/jm0601856",
"article-title": "Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities",
"author": "Biot",
"doi-asserted-by": "crossref",
"first-page": "2845",
"journal-title": "J Med Chem",
"key": "10.1016/j.ijantimicag.2020.105949_bib0012",
"volume": "49",
"year": "2006"
},
{
"DOI": "10.1016/j.ophtha.2016.01.058",
"article-title": "Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)",
"author": "Marmor",
"doi-asserted-by": "crossref",
"first-page": "1386",
"issue": "6",
"journal-title": "Ophthalmology",
"key": "10.1016/j.ijantimicag.2020.105949_bib0013",
"volume": "123",
"year": "2016"
},
{
"DOI": "10.1093/cid/ciaa237",
"article-title": "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)",
"author": "Yao",
"doi-asserted-by": "crossref",
"journal-title": "Clin Infect Dis",
"key": "10.1016/j.ijantimicag.2020.105949_bib0014",
"year": "2020"
},
{
"DOI": "10.1001/archinte.159.2.167",
"article-title": "Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine",
"author": "Raoult",
"doi-asserted-by": "crossref",
"first-page": "167",
"issue": "2",
"journal-title": "Arch Intern Med",
"key": "10.1016/j.ijantimicag.2020.105949_bib0015",
"volume": "159",
"year": "1999"
},
{
"DOI": "10.1097/QCO.0000000000000489",
"article-title": "Whipple's disease and Tropheryma whipplei infections: when to suspect them and how to diagnose and treat them",
"author": "Lagier",
"doi-asserted-by": "crossref",
"first-page": "463",
"issue": "6",
"journal-title": "Curr Opin Infect Dis",
"key": "10.1016/j.ijantimicag.2020.105949_bib0016",
"volume": "31",
"year": "2018"
},
{
"DOI": "10.1016/j.tmaid.2020.101632",
"article-title": "Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot",
"author": "Amrane",
"doi-asserted-by": "crossref",
"journal-title": "Travel Med Infect Dis",
"key": "10.1016/j.ijantimicag.2020.105949_bib0017",
"year": "2020"
},
{
"DOI": "10.1016/j.jchromb.2017.06.011",
"article-title": "Simultaneous UHPLC-UV analysis of hydroxychloroquine, minocycline and doxycycline from serum samples for the therapeutic drug monitoring of Q fever and Whipple's disease",
"author": "Armstrong",
"doi-asserted-by": "crossref",
"first-page": "166",
"journal-title": "J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.",
"key": "10.1016/j.ijantimicag.2020.105949_bib0018",
"volume": "1060",
"year": "2017"
},
{
"DOI": "10.1016/S0140-6736(20)30566-3",
"article-title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
"author": "Zhou",
"doi-asserted-by": "crossref",
"journal-title": "Lancet",
"key": "10.1016/j.ijantimicag.2020.105949_bib0019",
"year": "2020"
},
{
"DOI": "10.1073/pnas.1618029113",
"article-title": "Zika virus cell tropism in the developing human brain and inhibition by azithromycin",
"author": "Retallack",
"doi-asserted-by": "crossref",
"first-page": "14408",
"issue": "50",
"journal-title": "Proc Natl Acad Sci U S A",
"key": "10.1016/j.ijantimicag.2020.105949_bib0020",
"volume": "113",
"year": "2016"
},
{
"DOI": "10.1021/acsinfecdis.5b00030",
"article-title": "Evaluation of Ebola Virus Inhibitors for Drug Repurposing",
"author": "Madrid",
"doi-asserted-by": "crossref",
"first-page": "317",
"issue": "7",
"journal-title": "ACS Infect Dis",
"key": "10.1016/j.ijantimicag.2020.105949_bib0021",
"volume": "1",
"year": "2015"
},
{
"DOI": "10.4172/1948-5964.1000173",
"article-title": "Azithromycin inhibits the replication of Zika virus",
"author": "Bosseboeuf",
"doi-asserted-by": "crossref",
"first-page": "6",
"issue": "1",
"journal-title": "J Antivirals Antiretrovirals",
"key": "10.1016/j.ijantimicag.2020.105949_bib0022",
"volume": "10",
"year": "2018"
},
{
"DOI": "10.1001/jama.2015.13896",
"article-title": "Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: A randomized clinical trial",
"author": "Bacharier",
"doi-asserted-by": "crossref",
"first-page": "2034",
"issue": "19",
"journal-title": "JAMA",
"key": "10.1016/j.ijantimicag.2020.105949_bib0023",
"volume": "314",
"year": "2015"
}
],
"reference-count": 23,
"references-count": 23,
"relation": {
"has-preprint": [
{
"asserted-by": "object",
"id": "10.1101/2020.03.16.20037135",
"id-type": "doi"
}
],
"has-review": [
{
"asserted-by": "object",
"id": "10.3410/f.737589198.793573012",
"id-type": "doi"
},
{
"asserted-by": "object",
"id": "10.3410/f.737589198.793575483",
"id-type": "doi"
},
{
"asserted-by": "object",
"id": "10.3410/f.737589198.793575078",
"id-type": "doi"
},
{
"asserted-by": "object",
"id": "10.3410/f.737589198.793575992",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0924857920300996"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Pharmacology (medical)",
"Infectious Diseases",
"Microbiology (medical)",
"General Medicine"
],
"subtitle": [],
"title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy",
"volume": "56"
}
